Drugging the lymphatic system: An emerging opportunity for cancer immunotherapy

Adv Drug Deliv Rev. 2022 Jan:180:114040. doi: 10.1016/j.addr.2021.114040. Epub 2021 Nov 8.

Authors

Takashi Nakamura¹, Susan N Thomas²

Affiliations

¹ Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12 Nishi 6, Sapporo, Hokkaido 060-0812, Japan. Electronic address: tnakam@pharm.hokudai.ac.jp.
² Georgie W. Woodruff School of Mechanical Engineering, Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, 315 Ferst Drive NW, Atlanta, GA 30332, United States. Electronic address: susan.thomas@gatech.edu.

PMID: 34763001
DOI: 10.1016/j.addr.2021.114040

No abstract available

Publication types

Editorial
Introductory Journal Article
Comment

MeSH terms

Humans
Immunotherapy*
Lymphatic System
Neoplasms*